Conference call to discuss TNX-103 (Oral Levosimendan) for the Treatment of PH-HFpEF will be held on November 13 at 4:30 pm. Webcast Link
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TENX:
- Tenax Therapeutics Reports Increased R&D Expenses Amid Clinical Trials
- Tenax Therapeutics reports Q3 EPS (40c), consensus ($1.12)
- TENX Earnings this Week: How Will it Perform?
- Tenax Therapeutics Advances Phase 3 Study on Levosimendan for PH-HFpEF
- Tenax Therapeutics management to meet with Piper Sandler